Fig. 4: In-vitro activation of immune response. | Nature Communications

Fig. 4: In-vitro activation of immune response.

From: Cascaded immunotherapy with implantable dual-drug depots sequentially releasing STING agonists and apoptosis inducers

Fig. 4

a Schematic diagram illustrating the experimental operation of evaluating the activation or polarization of APCs treated with B16F10 cell debris generated with the co-incubation of drug depots in the presence or absence of MS-F-MS. Representative flow cytometry zebra plots (b, c) and quantifications (d, e) of DC maturation assessed using JAWSII cells (b, d) and macrophage polarization estimated employing RAW264.7 cells (c, e) undergoing indicated treatments for 24 h (n = 3 independent experiments). Relative mRNA levels of (f) ifnb1 in JAWSII cells and (g) IFNB1 in THP1 cells subjected to indicated treatments for 6 h (n = 3 independent experiments). Representative flow cytometry half-overlapped histograms (h, j) and quantifications (i. k) of STING+ fluorescence in JAWSII (h, i) or THP1 (j, k) cells undergoing indicated treatments for 6 h (n = 3 independent experiments). Data are expressed as mean ± SD. Statistical significances were estimated by one-way ANOVA with Tukey’s multiple comparisons post hoc test. Source data are provided as a Source Data file.

Back to article page